Research programme: sclerostin inhibitors - Medtronic/OsteoGenix

Drug Profile

Research programme: sclerostin inhibitors - Medtronic/OsteoGenix

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Osteogenix
  • Class
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bone disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-disorders in USA
  • 15 Sep 2009 Pharmacodynamics data from a preclinical trial in Bone regeneration presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2009)
  • 26 Mar 2007 Preclinical trials in Bone regeneration in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top